

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16  
OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of February 2020**

Commission file number: 001- 38556

**ENTERA BIO LTD.**

(Translation of registrant's name into English)

**Kiryat Hadassah  
Minrav Building – Fifth Floor  
Jerusalem, Israel**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

CONTENTS

**Results of the Extraordinary General Meeting of the Shareholders**

On February 18, 2020, Entera Bio Ltd. (the “**Company**”) held an extraordinary general meeting of shareholders (the “**Meeting**”). At the Meeting, the Company’s shareholders voted on three proposals, each of which is described in more detail in the Company’s proxy statement for the Meeting attached as Exhibit 99.1 to the Report of Foreign Private Issuer on Form 6-K the Company filed with the Securities and Exchange Commission on January 14, 2020 (the “**Proxy Statement**”).

Based on the results and the majority requirements under the Israeli Companies Law 5759-1999 (the “**Companies Law**”) and the Company’s Articles of Association, the shareholders of the Company duly approved the following resolutions:

- (1) To ratify and approve the terms of compensation of Mr. Jonathan Lieber, our U.S.-based Chief Financial Officer, for a period commencing as of November 21, 2019, and onward (Proposal 1);
- (2) To ratify and approve the grant of 33,638 options to Mr. Sean Ellis, a non-executive director of the Company, as of November 18, 2019 (Proposal 2); and
- (3) To approve a private placement with D.N.A Biomedical Solutions Ltd., or DNA, our principal shareholder (Proposal 3).

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Entera Bio Ltd.  
(Registrant)

By: /s/ Mr. Adam Gridley  
Name: Adam Gridley  
Title: Chief Executive Officer

Date: February 19, 2020

---

---